Page last updated: 2024-11-05

ici 204,219 and Hepatorenal Syndrome

ici 204,219 has been researched along with Hepatorenal Syndrome in 1 studies

zafirlukast: a leukotriene D4 receptor antagonist

Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Capella, GL1

Other Studies

1 other study available for ici 204,219 and Hepatorenal Syndrome

ArticleYear
Anti-leukotriene drugs in the prevention and treatment of hepatorenal syndrome.
    Prostaglandins, leukotrienes, and essential fatty acids, 2003, Volume: 68, Issue:4

    Topics: Acetates; Arachidonic Acid; Cyclopropanes; Hepatorenal Syndrome; Humans; Hydroxyurea; Indoles; Leuko

2003